Tweet

Jonah Lupton

5 Apr, 4 tweets, 2 min read

I'm not sure who is selling $TMDX today but thank you for the gift because I'm buying your shares.

I'll keep betting on $TMDX because I've seen the competition and it sucks.

$TMDX OCS Heart vs. The Ice Cooler

$TMDX has their FDA panel hearing tomorrow; although these events are unpredictable I believe the data is overwhelming and $TMDX will eventually receive approval for DCD and DBD.

Please do your own due diligence.

This was my $TMDX writeup from February: jonahlupton.substack.com/p/tmdx-transme…

Pullback to 50d moving average: chrt.biz/TMDX/190744x4u…

I would not be surprised if funds were selling their shares and/or shorting $TMDX to put pressure on the stock price so they could load up on call options. Don't get shaken out of your highest conviction companies.

$TMDX up 8.5% after hours -- pretty obvious that big funds were manipulating the stock today to shake out retail investors and now they are piling back in 🙄

• • •

Missing some Tweet in this thread? You can try to force a refresh

This Thread may be Removed Anytime!

Twitter may remove this content at anytime! Save it as PDF for later use!

More from @JonahLupton

Jonah Lupton

@JonahLupton

7 Apr

Just wrapped up calls with one of the $INTZ analysts as well as Investor Relations -- I'm still very bullish on $INTZ.

$INTZ is a $450M company with 2022 revenue estimates of $55-65M which means 150% top line growth with 70% gross margins.

Intro video:

$INTZ has done DoD work for 30+ years ($8-10 million per year) but now they are taking all of that data & expertise to launch an enterprise product called Shield.

They are already closing deals with Fortune 500 companies: globenewswire.com/fr/news-releas…

They also have 22+ resellers that are selling their product (typically companies with under 100 employees)...

Read 4 tweets

Jonah Lupton

@JonahLupton

7 Apr

Congrats to $TMDX for receiving the approval vote from the FDA panel hearing on OCS Heart 🚀
prnewswire.com/news-releases/…

Even though yesterday was a big day for $TMDX shareholders the bigger catalyst is still coming when $TMDX gets approval for DCD (donation after circulatory death) who.int/servicedeliver…

We also have OCS Liver approval on the horizon.

Because of all these catalysts Jason Mills from Canaccord Genuity raised his price target last month to $79 (more than 100% upside from current prices) streetinsider.com/Analyst+Commen…

Read 6 tweets

Jonah Lupton

@JonahLupton

5 Apr

@ClearPointNeuro

My most recent Substack writeup just went out to all free subscribers (paid subscribers got it last Tuesday): jonahlupton.substack.com/p/clpt-clearpo…

The stock is $CLPT -- @ClearPointNeuro

$CLPT has FDA clearance and provides real-time MRI imaging several different functions/procedures.

The business model breaks down into 4 groups...

Real-time MRI imaging provides a safer, faster and more accurate solution for neurosurgeons...

Read 8 tweets

Jonah Lupton

@JonahLupton

31 Mar

@JaredSKaplan

Here's my interview from yesterday with @JaredSKaplan, CEO of @OppLoans -- the parent company is OppFi.com

@OppLoans is coming public via reverse merger with $FGNA which is backed by @CoachJoeMoglia and @kcerminara

@OppLoans

@OppLoans is building a digital-first banking/lending platform for the millions of unbanked and underbanked Americans

Fundamentals are very strong...

Read 7 tweets

Jonah Lupton

@JonahLupton

25 Mar

If you missed my "Investing for Beginners" webinar last night it's now on YouTube:

The webinar ended up going 2.5 hours because I felt it was important to cover as many topics as possible.

For anyone that is new to investing or wants to start investing, I hope this webinar is helpful for you.

Here are the slides if anyone wants to use them: docs.google.com/presentation/d…

You should be able to copy/paste these slides into your own presentation then edit them as you see fit.

Read 4 tweets